AU2003296647A1 - Use of a combination containing a non-nucleoside reverse transcriptase inhibitor (nnrti) with an inhibitor of cytochrome p450, such as protease inhibitors - Google Patents

Use of a combination containing a non-nucleoside reverse transcriptase inhibitor (nnrti) with an inhibitor of cytochrome p450, such as protease inhibitors Download PDF

Info

Publication number
AU2003296647A1
AU2003296647A1 AU2003296647A AU2003296647A AU2003296647A1 AU 2003296647 A1 AU2003296647 A1 AU 2003296647A1 AU 2003296647 A AU2003296647 A AU 2003296647A AU 2003296647 A AU2003296647 A AU 2003296647A AU 2003296647 A1 AU2003296647 A1 AU 2003296647A1
Authority
AU
Australia
Prior art keywords
compound
formula
inhibitor
pharmaceutically acceptable
combination according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003296647A
Other languages
English (en)
Inventor
Michael Graham Cordingley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of AU2003296647A1 publication Critical patent/AU2003296647A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003296647A 2002-12-16 2003-12-15 Use of a combination containing a non-nucleoside reverse transcriptase inhibitor (nnrti) with an inhibitor of cytochrome p450, such as protease inhibitors Abandoned AU2003296647A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43369002P 2002-12-16 2002-12-16
US60/433,690 2002-12-16
PCT/EP2003/014224 WO2004054586A1 (en) 2002-12-16 2003-12-15 Use of a combination containing a non-nucleoside reverse transcriptase inhibitor (nnrti) with an inhibitor of cytochrome p450, such as protease inhibitors

Publications (1)

Publication Number Publication Date
AU2003296647A1 true AU2003296647A1 (en) 2004-07-09

Family

ID=32595224

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003296647A Abandoned AU2003296647A1 (en) 2002-12-16 2003-12-15 Use of a combination containing a non-nucleoside reverse transcriptase inhibitor (nnrti) with an inhibitor of cytochrome p450, such as protease inhibitors

Country Status (20)

Country Link
US (2) US20040152625A1 (enExample)
EP (1) EP1575595A1 (enExample)
JP (1) JP2006511538A (enExample)
KR (1) KR20050085681A (enExample)
CN (1) CN1726041A (enExample)
AU (1) AU2003296647A1 (enExample)
BR (1) BR0317095A (enExample)
CA (1) CA2510143A1 (enExample)
EA (1) EA200500894A1 (enExample)
EC (1) ECSP055854A (enExample)
HR (1) HRP20050557A2 (enExample)
IL (1) IL169099A0 (enExample)
MX (1) MXPA05005773A (enExample)
NO (1) NO20053455L (enExample)
NZ (1) NZ541187A (enExample)
PL (1) PL376900A1 (enExample)
RS (1) RS20050461A (enExample)
UA (1) UA81003C2 (enExample)
WO (1) WO2004054586A1 (enExample)
ZA (1) ZA200502947B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1944042A1 (en) 2003-10-27 2008-07-16 Vertex Pharmceuticals Incorporated Combinations for HCV treatment
US7388008B2 (en) 2004-08-02 2008-06-17 Ambrilia Biopharma Inc. Lysine based compounds
EP1877091B1 (en) * 2005-04-27 2015-03-25 TaiMed Biologics, Inc. Method for improving pharmacokinetics of protease inhibitors and protease inhibitor precursors
JP2009517412A (ja) 2005-11-30 2009-04-30 アンブリリア バイオファーマ インコーポレイテッド アスパルチルプロテアーゼ阻害物質のリジンベースのプロドラッグ及びその調製方法
CN1907138B (zh) * 2006-08-11 2011-01-12 华南师范大学 一种沙田柚子汁提取物及其提取方法和应用
AU2007337830A1 (en) 2006-09-21 2008-07-03 Ambrilia Biopharma Inc. Benzenesulfonamide derivatives as HIV protease inhibitors
KR20130130875A (ko) 2009-02-27 2013-12-02 이난타 파마슈티칼스, 인코포레이티드 Ｃ형 간염 바이러스 억제제
EP2421527B1 (en) * 2009-04-25 2018-06-13 F.Hoffmann-La Roche Ag Methods for improving pharmacokinetics
MX2011012155A (es) 2009-05-13 2012-02-28 Enanta Pharm Inc Compuestos macrociclicos como inhibidores del virus de hepatitis c.
EP2512480A4 (en) 2009-12-14 2013-05-15 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
WO2014013014A1 (en) 2012-07-18 2014-01-23 Fundació Privada Centre De Regulació Genòmica (Crg) Jak inhibitors for activation of epidermal stem cell populations
WO2018041989A1 (en) 2016-09-02 2018-03-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating refractory celiac disease type 2
US20220177978A1 (en) 2019-04-02 2022-06-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
EP3955920A1 (en) 2019-04-16 2022-02-23 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels
EP4526469A1 (en) 2022-05-16 2025-03-26 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696270A (en) * 1989-05-23 1997-12-09 Abbott Laboratories Intermediate for making retroviral protease inhibiting compounds
IL111991A (en) * 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
JP2001518899A (ja) * 1997-04-07 2001-10-16 トライアングル ファーマシューティカルズ，インコーポレイティド 他の抗ウイルス剤との組合せにおけるｍｋｃ−４４２の使用
EP1126847A1 (en) * 1998-11-04 2001-08-29 PHARMACIA & UPJOHN COMPANY Method for improving the pharmacokinetics of tipranavir
US6391919B1 (en) * 2000-01-12 2002-05-21 Bristol-Myers Squibb Pharma Company Bis-amino acid sulfonamides containing substituted benzyl amines HIV protease inhibitors
TWI270547B (en) * 2000-06-16 2007-01-11 Boehringer Ingelheim Ca Ltd Non-nucleoside reverse transcriptase inhibitors
JP4391426B2 (ja) * 2002-09-19 2009-12-24 ベーリンガー インゲルハイム （カナダ） リミテッド 非ヌクレオシド逆転写酵素インヒビター

Also Published As

Publication number Publication date
BR0317095A (pt) 2005-10-25
PL376900A1 (pl) 2006-01-09
RS20050461A (sr) 2007-08-03
CN1726041A (zh) 2006-01-25
EP1575595A1 (en) 2005-09-21
JP2006511538A (ja) 2006-04-06
ECSP055854A (es) 2006-01-16
ZA200502947B (en) 2008-01-30
NO20053455L (no) 2005-08-10
HRP20050557A2 (en) 2006-05-31
CA2510143A1 (en) 2004-07-01
US20080096832A1 (en) 2008-04-24
KR20050085681A (ko) 2005-08-29
IL169099A0 (en) 2007-07-04
UA81003C2 (en) 2007-11-26
NZ541187A (en) 2007-12-21
EA200500894A1 (ru) 2006-02-24
MXPA05005773A (es) 2005-08-16
WO2004054586A1 (en) 2004-07-01
US20040152625A1 (en) 2004-08-05

Similar Documents

Publication Publication Date Title
US20080096832A1 (en) Method for Improving the Pharmacokinetics of an NNRTI
US6245789B1 (en) HIV and viral treatment
JP5769763B2 (ja) 治療用組成物およびその使用
JP5769762B2 (ja) 治療組成物およびその使用
KR101951220B1 (ko) 조합 als 치료법
CA2664935A1 (en) Compositions for the treatment of hepatitis c and methods for using compositions for the treatment of hepatitis c
RU2494736C2 (ru) Комбинация, включающая паклитаксел, для лечения рака яичников
US20060229293A1 (en) Compositions for the treatment of hepatitis C and methods for using compositions for the treatment of hepatitis C
US20140275139A1 (en) Mdr method and products for treating hiv/aids
EP1503756B1 (en) Epothilone derivative for the treatment of hepatoma and other cancer diseases
US6498173B1 (en) Synergistic combination comprising roflumilast and a pde-3 inhibitor
KR930007252B1 (ko) 우울증 치료용 약학조성물
JP5469095B2 (ja) 急性マラリアを治療するためのビス−チアゾリウム塩またはこれらの前駆体およびアルテミシニンまたはこれらの誘導体の組み合わせ
JPWO2021216385A5 (enExample)
HK1085921A (en) Use of a combination containing a non-nucleoside reverse transcriptase inhibitor (nnrti) with an inhibitor of cytochrome p450, such as protease inhibitors
JPS62267227A (ja) 血中尿酸濃度の低下用医薬
KR20220099435A (ko) ＳＡＲＳ-ＣｏＶ-2 감염증 치료 또는 예방용 약학 조성물
JP2018534322A (ja) Ｈｉｖ成熟阻害剤製剤
HK1152892B (en) Combination of a bis-thiazolium salt or a precursor thereof and artemisinin or a derivative thereof for treating acute malaria
HK1073601B (en) Epothilone derivative for the treatment of hepatoma and other cancer diseases

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application